Literature DB >> 31196652

The Natural History of Rheumatoid Arthritis.

Kevin D Deane1, V Michael Holers2.   

Abstract

PURPOSE: This article reviews the phases of rheumatoid arthritis (RA) development in terms of the evolution of disease, with a focus on events that occur before the first appearance of clinically apparent inflammatory arthritis. This presynovitis period is defined in individuals who eventually develop classified RA as the pre-RA phase. We include additional discussion of the relevance of this model of RA development to the concept of disease prevention.
METHODS: The information provided in this review was identified through searches of the medical literature through MEDLINE and a review of references from published manuscripts as well as information obtained by the authors through attendance at various conferences and working groups related to pre-RA.
FINDINGS: It is now well established that RA develops in a series of phases. The first of these phases is believed to be the presence of genetic and/or environmental risk factors for RA in the absence of detectable systemic autoimmunity in the blood. After this phase, autoimmunity may be detectable through a variety of means (eg, autoantibodies, autoreactive cells) in peripheral blood; in addition, there is emerging evidence that perhaps initiation and early propagation of RA-related autoimmunity may occur at mucosal sites. The presence of autoimmunity detectable in the blood through serologic or other testing is followed in most individuals by a propagation phase that is characterized by an expansion of autoimmunity, inflammation, and symptoms. This transition may be associated with similar or different genetic and environmental factors that initially triggered autoimmunity, as well as continued mucosal inflammation and local RA-related autoantibody production. Eventually, clinically detectable inflammatory arthritis develops that can be classified as RA. IMPLICATIONS: Understanding the phases of RA development are critical to the development of preventive strategies for this disease.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  disease prevention; inflammatory arthritis; pre–rheumatoid arthritis; rheumatoid arthritis

Mesh:

Substances:

Year:  2019        PMID: 31196652     DOI: 10.1016/j.clinthera.2019.04.028

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  15 in total

1.  Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis.

Authors:  Kathleen Tymms; Belinda Butcher; Tegan Smith; Geoffrey Littlejohn
Journal:  Eur J Rheumatol       Date:  2020-09-18

2.  Patients with rheumatoid arthritis have an increased risk of incident chronic kidney disease: a systematic review and meta-analysis of cohort studies.

Authors:  Sukit Raksasuk; Patompong Ungprasert
Journal:  Int Urol Nephrol       Date:  2019-12-09       Impact factor: 2.370

3.  Diagnostic accuracy of digital X-ray radiogrammetry on hand bone loss for patients with rheumatoid arthritis.

Authors:  Hong-Jian An; Jun Zhang
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

4.  Cohort profile of a US military population for evaluating pre-disease and disease serological biomarkers in rheumatoid and reactive arthritis: Rationale, organization, design, and baseline characteristics.

Authors:  Chad K Porter; Mark S Riddle; Renee M Laird; Matthew Loza; Suzanne Cole; Christina Gariepy; Ashley Alcala; Ramiro Gutierréz; Frédéric Baribaud; Navin L Rao; Sunil Nagpal
Journal:  Contemp Clin Trials Commun       Date:  2020-01-14

5.  Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis.

Authors:  Jing Song; Anja Schwenzer; Alicia Wong; Sara Turcinov; Cliff Rims; Lorena Rodriguez Martinez; David Arribas-Layton; Christina Gerstner; Virginia S Muir; Kim S Midwood; Vivianne Malmström; Eddie A James; Jane H Buckner
Journal:  JCI Insight       Date:  2021-03-08

Review 6.  Non-Oncologic Applications of Nanomedicine-Based Phototherapy.

Authors:  Su Woong Yoo; Gyungseok Oh; Jin Chul Ahn; Euiheon Chung
Journal:  Biomedicines       Date:  2021-01-25

7.  Rheumatoid Arthritis Susceptibility Is Associated with the KIR2DS4-Full of Killer-Cell Immunoglobulin-Like Receptor Genes in the Lur Population of Iran.

Authors:  Bijan Ansari-Moghaddam; Ali Asghar Kiani; Ali Sheikhian; Mehdi Birjandi; Seyyed Amir Yasin Ahmadi; Nazanin Mousavi; Hamzeh Ali Torang; Farhad Shahsavar
Journal:  Rep Biochem Mol Biol       Date:  2021-04

Review 8.  The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Authors:  Shahin Shams; Joseph M Martinez; John R D Dawson; Juan Flores; Marina Gabriel; Gustavo Garcia; Amanda Guevara; Kaitlin Murray; Noah Pacifici; Maxemiliano V Vargas; Taylor Voelker; Johannes W Hell; Judith F Ashouri
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

Review 9.  The metabolic signature of T cells in rheumatoid arthritis.

Authors:  Cornelia M Weyand; Bowen Wu; Jörg J Goronzy
Journal:  Curr Opin Rheumatol       Date:  2020-03       Impact factor: 4.941

10.  Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Authors:  Jan Vollert; Nancy R Cook; Ted J Kaptchuk; Shiv T Sehra; Deirdre K Tobias; Kathryn T Hall
Journal:  JAMA Netw Open       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.